Business
Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes Science and Technology, a leading US Publication for Diabetes
Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes Science and Technology, a leading US Publication for Diabetes.
About this update from Viaderma, Inc.
[{"type":"text","content":"\nDr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article \"Healing Diabetic Ulcers with a New Topical Antibiotic Ointment\" for the Journal of Diabetes Science and Technology, a leading US Publication for Diabetes\n\nDr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article \"Healing Diabetic Ulcers with a New Topical Antibiotic Ointment\" for the Journal of Diabetes Science and Technology, a leading US Publication for Diabetes\n\n\nJournal of DST is a Peer-Reviewed Bi-monthly Scientific Journal Indexed in the National Library of Medicine's Database, PubMed. They Publish the Largest Number of Articles on Diabetes Technology of any Journal in the World\n\n LOS ANGELES, CA--(Marketwired - February 08, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the President, Dr. Christopher Otiko has been invited to write an article in a leading Diabetic publication, the \"Journal of Diabetes Science and Technology.\" Dr. Otiko has also been selected to present his abstract at DFCON or the Diabetic Foot Global Conference in Houston, TX, March 23rd through the 25th. DFCon, website www.dfcon.com, is the premier international, interdisciplinary diabetic foot conference in North America. In its 15th year, the course is designed for the wide spectrum of generalists and specialists who diagnose and manage the diabetic foot. Didactic talks, panel discussions, Q&A sessions, specialty symposia and workshops will delve into diagnostic and interventional strategies for diabetic foot ulcers and amputation prevention. Featuring a world-renowned international faculty, DFCon offers the opportunity to review state-of-the-art concepts and techniques. \"Diabetes affects almost a half a billion people globally with 23 million affected in the US. With about 83 million affected with condition designated as pre-diabetes. Of those with diabetes, 50% will develop peripheral neuropathy and/or diabetic ulcers. Of the 23 million people affected with diabetes, 25% will develop diabetic ulcers many will require expensive therapy or invasive surgical amputations. The goal of this study was to evaluate the efficacy and safety of the FDA registered OTC medication Viabecline. A topically applied antibiotic ointment desig...